Activation of Pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells

Neoplasia

Volumn 13, Issue 9, 2011, Pages 806-821

  Bekes, Erin M ^a   Deryugina, Elena I ^a   Kupriyanova, Tatyana A ^a   Zajac, Ewa ^a   Botkjaer, Kenneth A ^b   Andreasen, Peter A ^b   Quigley, James P ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 112; PLASMIN; PROUROKINASE; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CARCINOGENESIS; CARCINOMA CELL; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RISK FACTOR; TUMOR ESCAPE; TUMOR XENOGRAFT;

EID: 80053458622     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11704     Document Type: Article

References (54)

1. Duffy MJ, McGowan PM, and Gallagher WM (2008). Cancer invasion and metastasis: changing views. J Pathol 214, 283-293.
2. Kessenbrock K, Plaks V, and Werb Z (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67.
3. Usher PA, Thomsen OF, Iversen P, Johnsen M, Brunner N, Hoyer-Hansen G, Andreasen P, Dano K, and Nielsen BS (2005). Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer 113, 870-880.
4. Cozzi PJ, Wang J, Delprado W, Madigan MC, Fairy S, Russell PJ, and Li Y (2006). Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum Pathol 37, 1442-1451.
5. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, and Slawin KM (2007). Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 25, 349-355.
6. Li Y and Cozzi PJ (2007). Targeting uPA/uPAR in prostate cancer. Cancer Treat Rev 33, 521-527.
7. Andreasen PA, Egelund R, and Petersen HH (2000). The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57, 25-40.
8. Behrendt N, List K, Andreasen PA, and Dano K (2003). The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Biochem J 371, 277-287.
9. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M, and Romer J (2005). Plasminogen activation and cancer. Thromb Haemost 93, 676-681.
10. Vincenza C.M, Franco P, Vocca I, Alfano D, Longanesi-Cattani I, Bifulco K, Mancini A, Caputi M, and Stoppelli MP (2009). Structure, function and antagonists of urokinase-type plasminogen activator. Front Biosci 14, 3782-3794.
11. Blasi F and Carmeliet P (2002). uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3, 932-943.
12. Binder BR, Mihaly J, and Prager GW (2007). uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 97, 336-342.
13. Ellis V, Behrendt N, and Dano K (1991). Plasminogen activation by receptorbound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266, 12752-12758.
14. Hajjar KA, Jacovina AT, and Chacko J (1994). An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 269, 21191-21197.
15. Andronicos NM, Chen EI, Baik N, Bai H, Parmer CM, Kiosses WB, Kamps MP, Yates JR III, Parmer RJ, and Miles LA (2010). Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation. Blood 115, 1319-1330.
16. Myohanen H and Vaheri A (2004). Regulation and interactions in the activation of cell-associated plasminogen. Cell Mol Life Sci 61, 2840-2858.
17. Quigley JP, Gold LI, Schwimmer R, and Sullivan LM (1987). Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells. Proc Natl Acad Sci USA 84, 2776-2780.
18. Goldfinger LE, Stack MS, and Jones JC (1998). Processing of laminin-5 and its functional consequences: role of plasmin and tissue-type plasminogen activator. J Cell Biol 141, 255-265.
19. Pankov R and Yamada KM (2002). Fibronectin at a glance. J Cell Sci 115, 3861-3863.
20. Murphy G, Stanton H, Cowell S, Butler G, Knauper V, Atkinson S, and Gavrilovic J (1999). Mechanisms for pro matrix metalloproteinase activation. APMIS 107, 38-44.
21. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, and Quigley JP (1999). Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274, 13066-13076.
22. Sheng S (2001). The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev 20, 287-296.
23. Sidenius N and Blasi F (2003). The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22, 205-222.
24. Rockway TW, Nienaber V, and Giranda VL (2002). Inhibitors of the protease domain of urokinase-type plasminogen activator. Curr Pharm Des 8, 2541-2558.
25. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, and Rao JS (2005). RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280, 36529-36540.
26. Pulukuri SM, Estes N, Patel J, and Rao JS (2007). Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res 67, 930-939.
27. Dong Z, Saliganan AD, Meng H, Nabha SM, Sabbota AL, Sheng S, Bonfil RD, and Cher ML (2008). Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. Neoplasia 10, 439-449.
28. Pulukuri SM and Rao JS (2007). Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis. Cancer Res 67, 6637-6646.
29. Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJ, and Degen JL (1996). Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 87, 709-719.
30. Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmback K, Drew AF, Flick MJ, Witte DP, Dano K, and Degen JL (1998). Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogendeficient mice. Oncogene 16, 3097-3104.
31. Almholt K, Lund LR, Rygaard J, Nielsen BS, Dano K, Romer J, and Johnsen M (2005). Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 113, 525-532.
32. Madsen MA, Deryugina EI, Niessen S, Cravatt BF, and Quigley JP (2006). Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation. J Biol Chem 281, 15997-16005.
33. Blouse GE, Botkjaer KA, Deryugina E, Byszuk AA, Jensen JM, Mortensen KK, Quigley JP, and Andreasen PA (2009). A novel mode of intervention with serine protease activity: targeting zymogen activation. J Biol Chem 284, 4647-4657.
34. Conn EM, Botkjaer KA, Kupriyanova TA, Andreasen PA, Deryugina EI, and Quigley JP (2009). Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion. Am J Pathol 175, 1638-1652.
35. Deryugina EI, Zijlstra A, Partridge JJ, Kupriyanova TA, Madsen MA, Papagiannakopoulos T, and Quigley JP (2005). Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Cancer Res 65, 10959-10969.
36. Zijlstra A, Mellor R, Panzarella G, Aimes RT, Hooper JD, Marchenko ND, and Quigley JP (2002). A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. Cancer Res 62, 7083-7092.
37. Moran P, Li W, Fan B, Vij R, Eigenbrot C, and Kirchhofer D (2006). Pro-urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem 281, 30439-30446.
38. Lee SL, Dickson RB, and Lin CY (2000). Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 275, 36720-36725.
39. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, and Craik CS (2000). Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275, 26333-26342.
40. Pilcher BK, Dumin JA, Sudbeck BD, Krane SM, Welgus HG, and Parks WC (1997). The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J Cell Biol 137, 1445-1457.
41. Zijlstra A, Aimes RT, Zhu D, Regazzoni K, Kupriyanova T, Seandel M, Deryugina EI, and Quigley JP (2004). Collagenolysis-dependent angiogenesis mediated by matrix metalloproteinase-13 (collagenase-3). J Biol Chem 279, 27633-27645.
42. Janssens M, Joris J, David JL, Lemaire R, and Lamy M (1994). High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Anesthesiology 80, 23-29.
43. Stassen JM, Lambeir AM, Matthyssens G, Ripka WC, Nystrom A, Sixma JJ, and Vermylen J (1995). Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties. Thromb Haemost 74, 646-654.
44. Kontermann RE (2009). Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 23, 93-109.
45. Kirstein JM, Graham KC, Mackenzie LT, Johnston DE, Martin LJ, Tuck AB, MacDonald IC, and Chambers AF (2009). Effect of anti-fibrinolytic therapy on experimental melanoma metastasis. Clin Exp Metastasis 26, 121-131.
46. Erpenbeck L and Schon MP (2010). Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 115, 3427-3436.
47. Gay LJ and Felding-Habermann B (2011). Contribution of platelets to tumour metastasis. Nat Rev Cancer 11, 123-134.
48. Sabbota AL, Kim HR, Zhe X, Fridman R, Bonfil RD, and Cher ML (2010). Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res 70, 5558-5566.
49. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, Massague J, and Kang Y (2009). ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 23, 1882-1894.
50. Palumbo JS, Talmage KE, Liu H, La Jeunesse CM, Witte DP, and Degen JL (2003). Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency. Blood 102, 2819-2827.
51. Selvarajan S, Lund LR, Takeuchi T, Craik CS, and Werb Z (2001). A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation. Nat Cell Biol 3, 267-275.
52. Akiyama SK, Olden K, and Yamada KM (1995). Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev 14, 173-189.
53. Hynes RO (1999). Fibronectins. In Guidebook to the Extracellular Matrix, Anchor and Adhesion Proteins. T Kreis and R Vale (Eds). Oxford University Press, New York, NY. pp. 422-425.
54. Ruoslahti E (2003). RGD story: a personal account. A landmark essay. Matrix Biol 22, 459-465.